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a b s t r a c t
We describe, for the first time, hydrogel-forming microneedle (s) (MN) arrays for minimally-invasive
extraction and quantification of lithium in vitro and in vivo. MN arrays, prepared from aqueous blends
of hydrolysed poly(methyl-vinylether-co-maleic anhydride) and crosslinked by poly(ethyleneglycol),
imbibed interstitial fluid (ISF) upon skin insertion. Such MN were always removed intact. In vitro, mean
detected lithium concentrations showed no significant difference following 30 min MN application to
excised neonatal porcine skin for lithium citrate concentrations of 0.9 and 2 mmol/l. However, after
1 h application, the mean lithium concentrations extracted were significantly different, being appropri-
ately concentration-dependent. In vivo, rats were orally dosed with lithium citrate equivalent to
15 mg/kg and 30 mg/kg lithium carbonate, respectively. MN arrays were applied 1 h after dosing and
removed 1 h later. The two groups, having received different doses, showed no significant difference
between lithium concentrations in serum or MN. However, the higher dosed rats demonstrated a lithium
concentration extracted from MN arrays equivalent to a mean increase of 22.5% compared to rats which
received the lower dose. Hydrogel-forming MN clearly have potential as a minimally-invasive tool for
lithium monitoring in outpatient settings. We will now focus on correlation between serum and MN
lithium concentrations.
 2016 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Despite the introduction of a wide range of mood stabilizing
agents, lithium is still considered the ‘gold standard’ treatment
for bipolar (BP) disorder [1,2]. As a pharmacological agent, lithium
is a cornerstone of neuropsychopharmacology, primarily used to
treat BP affective disorder, where it can improve both manic and
depressive symptoms [3]. In addition, it also has many off-label
uses, including treatment of alcoholism, hyperthyroidism, person-
ality disorders, traumatic brain injury, tardive dyskinesia and
postpartum affective psychosis [4]. Lithium, like all alkali metals,
is highly reactive [5]. Therefore, it readily forms, and can be admin-
istered as, salts such as citrate, sulphate, chloride and, most com-
monly, carbonate. These salts are available in several different
dosage forms, such as syrup and both conventional and sustained
release tablets and capsules [4,6].
Early studies reported the effects of lithium on many neuro-
transmitter and neuromodulatory systems such as the cholinergic,
monoaminergic and gamma-aminobutyric acid (GABA) systems
[7]. Many theories speculate on the mechanism of lithium’s mood
stabilizing action. The initial accepted mechanism of action (MOA)
of lithium in BP disorder suggested that lithium interfered with
neuronal sodium–potassium electrogenic pumps and, in doing so,
altered synaptic transmission [6,7]. However, recent evidence has
indicated that lithium may have several MOA, including a direct
effect on glutamatergic neural transmission, notably via neuronal
excitability at hippocampal cornu ammonis (CA) 1 synapses,
thereby improving the excitatory postsynaptic potentials [7].
http://dx.doi.org/10.1016/j.ejpb.2016.03.009
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Following oral administration, lithium is rapidly absorbed from
the gastrointestinal tract (GIT) with a peak plasma concentration
(Cpmax) achieved after 1–5 h, and a half-life (t½) of approximately
22 h [8]. In addition, lithium does not bind to plasma proteins,
has a large volume of distribution (Vd) and can accumulate in
many tissues [9]. Depending on its formulation, it has an
80–100% oral bioavailability and steady state concentration (Cpss)
in blood is typically achieved within 4–5 days of starting treatment
[8–10]. More than 95% of lithium is excreted unchanged through
the kidneys. Over 80% of filtered lithium is reabsorbed in the prox-
imal tubules and at Cpss, lithium clearance is directly proportional
to the glomerular filtration rate (GFR) [9–11]. The clinically effec-
tive plasma concentration of lithium in human typically ranges
from 0.4 to 1.2 mmol/l. This narrow therapeutic window can pre-
dispose patients to lithium toxicity with even minor changes in
health status or co-prescribed medications. As such, continued
lithium therapy requires regular therapeutic drug monitoring
(TDM) to ensure optimum clinical benefits without the risk of tox-
icity [6]. Lithium toxicity in humans is a life threatening condition
and typically occurs when serum concentrations exceed 1.5 mmol/
l. Adverse effects include muscle weakness, coarse tremor, slurred
speech, seizures and irreversible renal damage. Adverse effects of
lithium on the kidney and thyroid gland have also been observed
during long term use, even when a serum concentration is main-
tained within the recommended therapeutic window [12]. More-
over, the combination of a reduced Vd and reduced renal
clearance of lithium in the elderly frequently leads to a lower tol-
erability with increasing age and, therefore, neurotoxicity may
occur in the elderly at concentrations considered therapeutic in
healthy adult populations [13]. Therefore, accurate, precise and
regular TDM of lithium is crucial to ensure safe and beneficial
treatment of patients. Typical regimes suggest that, upon com-
mencement of lithium therapy, TDM should be performed on a
weekly basis. However, once the patient is established on their
required therapeutic dose, TDM is typically only performed
monthly [14] (see Figs. 1 and 2).
Clinical laboratories employ several methods for the
measurement of lithium in serum. These include flame atomic
absorption spectrometry (FAAS), flame emission spectrometry
(FES), inductively-coupled plasma mass spectrometry (MS) and
ion-selective electrodes (ISE) [15,16]. Colorimetric, photometric
and enzymatic methods have also been used for TDM purposes
[16]. Of these methods, FAAS is the most commonly used tech-
nique, due to its sensitivity and simplicity [15–17]. Despite the
valuable clinical data provided by TDM, its practical application
in clinical settings can be greatly limited by the high cost and
time-consuming nature of analytical procedures, as TDM requires
repetitive withdrawal of blood samples by nursing or medically-
trained personnel using hypodermic needles [18]. Sampling is,
therefore, invasive and often painful, especially in patients with
difficult venous access [19,20]. In addition to the need for trained
personnel, the use of conventional needles is often associated with
a risk of infection or transmission of blood-borne diseases, due to
accidental needle-stick injuries and/or improper needle disposal
[20]. Notably, previous attempts to monitor lithium using either
saliva or urine, as alternatives to TDM using blood, have not proven
to be successful [20,21]. Therefore, developing a minimally-
invasive method would be a major advance in lithium TDM, allow-
ing non-medically trained personnel, or the patient themselves, to
monitor their lithium levels, thus ensuring patients are receiving
the optimum dose.
ISF has previously been proposed as a viable alternative to
plasma or serum as a source for TDM [22]. The composition of
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Fig. 1. Diagrammatic representation of steps involved in the preparation of polymeric MN. (A) Polymer matrix was transferred to the silicone mould and (B) centrifuged at
3500 rpm for 15 min. Upon drying for 48 h (C) and heating for 24 h at 80 C (D) to induce crosslinking via esterification, the silicone mould was carefully peeled away from the
polymeric MN array (E) and side walls removed using a hot scalpel blade (F).
Movable aluminium probe
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Fig. 2. Texture Analyser set-up for application of compressional forces to MN array.
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ISF closely resembles that of plasma, but without the plasma pro-
teins. Sampling ISF is a potentially non-invasive and painless pro-
cedure. In addition, sample preparation and analysis of ISF can be
simpler than those of blood, as it contains smaller quantities of
cells and proteins [22]. Reverse iontophoresis (RI) has previously
been proposed as a viable non-invasive sampling method for
lithium TDM, using ISF as an alternative TDM sampling reservoir
[19]. However, RI has several problematic issues. These include
the need for relatively complicated technology, a ‘warm-up’ time
of 2–3 h and the need for preliminary calibration [19,23,24]. These
issues present obvious practical problems which could potentially
preclude their use by non-trained personnel. Furthermore, in
developing countries, where access to the appropriate technology
may be limited, the cost of suitable RI equipment may be
prohibitive.
MN arrays have recently been proposed by our Group as an
alternative approach for sampling ISF [20]. MN arrays are com-
posed of tiny projections (50–900 lm in height) attached to a base
support, as previously described [25]. Upon insertion into the skin,
MN bypass the stratum corneum, the skin’s outermost barrier layer,
and extract ISF without causing pain or bleeding [20,23]. Although
MN arrays have been fabricated from a range of materials, includ-
ing metal, silicon and biodegradable polymers [26] our Group has
focused on MN prepared from hydrogel-forming polymers [27].
Such systems consist of a cross-linked polymer network that, upon
contact with an aqueous solution, swell to several times their orig-
inal volume whilst remaining insoluble, therefore maintaining
their structural integrity [28]. In their dry state, hydrogel-
forming MN possess sufficient mechanical strength to pierce the
stratum corneum. However, once in situ they rapidly uptake ISF
and, in doing so, can obtain a sample of the analyte of interest.
The MN can then be removed intact, allowing subsequent extrac-
tion and analysis of the analyte of interest.
Here we describe, for the first time, the use of our hydrogel-
forming MN to detect lithium via ISF in vivo. This study aims to
evaluate the potential of hydrogel-forming MN as a minimally-
invasive tool for in vivo transdermal lithium monitoring.
2. Material and methods
All animal experiments throughout this study were approved
by the Ethics Committee of the QUB Biological Services Unit and
conducted according to the policy of the Federation of European
Laboratory Animal Science Associations (FELASA) and The Euro-
pean Convention for the protection of Vertebrate Animals used
for Experimental and Other Scientific Purposes, with implementa-
tion of the principle of the 3Rs (replacement, reduction, refine-
ment). Any animals with 20% weight loss during the study were
to be removed for euthanasia, but this did not occur. No skin reac-
tions to MN occurred either. At the end of the experiment, eutha-
nasia was by carbon dioxide.
2.1. Chemicals
Poly(methylvinylether-co-maelic anhydride) (PMVE/MA) (Gan-
trez AN-139) was a gift from Ashland (Kidderminster, UK). Poly
(ethyleneglycol) (PEG) 10,000 daltons and lithium citrate hydrate
were obtained from Sigma–Aldrich, Poole, Dorset, UK. Isoflurane
(Isoflo) was obtained from Abbott Laboratories, Illinois, USA.
Reference-grade lithium analytical solution (1000 mg/l) was
obtained from J.T. Baker, Radnor, USA. Syringe filters (0.2 lm cellu-
lose acetate) were obtained from Chromacol, Herts, UK. All other
chemicals were of analytical reagent grade. Millipore HPLC-grade
water was used throughout the study.
2.2. Preparation of hydrogel-forming MN
Aqueous blends containing hydrolysed PMVE/MA (11.1%) and
PEG 10,000 (5.6%) were used to fabricate MN arrays (19  19
arrays, 600 lm in height, with a base width of 300 lm and inter-
spacing of 50 lm) by using laser-engineered silicone micromould
templates [27,29]. MN were crosslinked (esterification reaction)
[30] by heating at 80 C for 24 h and sidewalls removed using a
heated blade [27,29]. Formulation and mechanical properties of
such hydrogel-forming MN have previously been reported [31].
2.3. Mechanical analysis
A TA.XT-plus Texture Analyser (Stable Microsystem, Haslemere,
UK) was employed in compression mode, as previously described
[31], to investigate the application of varying axial compression
loads on the fabricated hydrogel-forming MN arrays. MN were
examined under a light microscope (GXMGE-5 digital microscope,
Laboratory Analysis Ltd., Devon, UK) before and after application of
the compression load to assess the percentage height reduction.
Compression forces of 0.18 and 0.7 Newtons (N) per needle were
applied, values which are approximately double and tenfold the
average manual application force of 30 N (0.083 N/needle), as pre-
viously reported [32].
2.4. Optical coherence tomography
Optical coherence tomography (OCT) was used to evaluate the
MN penetration characteristics into full thickness neonatal porcine
skin (1.0 mm), a good model for human skin [33], obtained from
still-born piglets, in vitro. Hydrogel-forming MN arrays were
inserted into porcine skin using manual force (thumb pressure)
for 60 s, after which adhesive tape was applied to keep them in
place. OCT imaging was used to visualize in situ MN penetration
as previously described [34]. Images obtained were analysed using
Image J software (National Institutes of Health, Bethesda, MD,
USA). Depth and the pore diameter created by MN arrays were
measured using Ability Photopaint Version 4.1.4 (Ability Plus
Software Ltd., Crawley, UK) which added additional colour, thereby
enhancing the contrast between the skin layer and MN arrays.
2.5. In skin-swelling study
The in-skin swelling characteristics of hydrogel-forming MN
arrays were investigated using full-thickness neonatal porcine
skin. Prior to testing, the height and base width of 10 MN arrays
were measured using a digital light microscope (GXMGE-5 digital
microscope, Laboratory Analysis Ltd., Devon, UK). Skin samples
were gently shaved and equilibrated in phosphate buffered saline
(PBS, pH 7.4) for 15 min. A circular specimen of skin was then dried
and mounted on a modified Franz diffusion cell (15 mm orifice
diameter, synchronous stirring at 600 rpm and thermostated at
37 ± 1 C, Crown Glass Co. Inc., Sommerville, NJ, USA) using
cynoacrylate adhesive (Loctite Ltd., Dublin, Ireland), with the stra-
tum corneum accessed as previously described [34]. MN were kept
in the skin for 1 h before careful removal and visualization using
digital microscopy, which measured both height and width of
MN tested. Skin barrier integrity was confirmed as maintained,
post-shaving, by using trans-epidermal water loss (TEWL) mea-
surements from a Delfin Vapometer (Delfin Technologies, Surrey,
UK).
2.6. Preliminary drug uptake and ability to release study
Preliminary investigations into drug uptake and release were
carried out by swelling hydrogel-forming MN arrays for 30 min
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in weighing boats containing 20 ml of lithium citrate in PBS solu-
tion. Concentrations equivalent to 0.9 and 2 mmol/l lithium car-
bonate were chosen to replicate therapeutic and toxic
concentrations in humans, respectively [35]. After 30 min, MN
arrays were removed from the weighing boats, surface PBS
removed using filter paper and the MN placed into glass vials.
The lithium taken up by the MN was extracted using three differ-
ent release media: (A) deionized water, (B) 2% v/v hydrochloric
acid (HCl, pH = 0.85) and (C) 0.1% w/v potassium chloride (KCl).
Three ml of each medium was added separately to each vial con-
taining a swollen MN, and the contents allowed to settle for one
min. Each vial was subsequently vortexed for 1 min and all free
fluid in each vial collected, filtered and analysed using FAAS at a
wavelength of 670.8 nm.
2.7. Lithium recovery from MN
To confirm reproducable recovery of lithium from MN and
demonstrate an acceptable extraction efficiency using KCl as an
extraction medium, 15 ll of a lithium carbonate standard solution
(1000 lg/ml) was spiked onto a MN array. Extraction of spiked
lithium from each MN was then performed by placing the spiked
MN array into a sterile glass vial containing 2 ml of a 0.1% w/v
KCl solution as the extraction medium. As described previously,
the glass vial was allowed to settle for one min and vortexed for
one min and the remaining free solution was filtered using a
0.2 lm cellulose acetate syringe filter. The filtrate was then aspi-
rated into a FAAS machine for analysis. The percentage recovery
(extraction efficiency) was calculated according to Eq. (1):
2.8. In vitro lithium uptake
In vitroMN-mediated lithium monitoring was conducted across
dermatomed neonatal porcine skin (300–400 lm thickness), previ-
ously demonstrated as a suitable skin model to predict MN perfor-
mance in vivo [36]. The neonatal porcine skin was mounted on a
modified Franz-cell set-up, as previously described [34] and MN
arrays were applied under thumb pressure and held for 60 s. The
in vitro uptake study was carried out using Franz-cell receptor
chambers thermostated at 37 ± 1 C, containing two different con-
centrations of lithium citrate equivalent to 0.9 and 2 mmol/l
lithium carbonate. MN arrays were removed at 30 min and 1 h,
and lithium was extracted, as outlined above.
2.9. In vivo MN lithium monitoring
Six healthy male SD rats, aged 11–14 weeks and weighing
300–400 g, were divided into two groups (1 and 2), with three rats
in each group. Groups 1 and 2 were administered lithium citrate,
via oral gavage, equivalent to 15 and 30 mg/kg body weight,
respectively. Lithium was dosed in the form of the citrate salt
rather than lithium carbonate due to lithium citrate’s higher water
solubility at room temperature (74.5 g/100 g) compared to that of
lithium carbonate (1.29 g/100 g) [37]. One h after gavage, four MN
arrays were applied to the shaved, hairless back of each SD rat and
left in place for 1 h. TEWL measurements were again used to con-
firm maintenance of skin barrier function. An adhesive patch was
then applied to further secure the MN arrays, whilst an occlusive
dressing was applied to cover the surrounding area to prevent
the rats from removing the MN arrays [38]. Following MN removal,
blood samples were collected via cardiac puncture.
2.10. Serum preparation method
For assay method development, fresh rat blood was obtained
from healthy SD rats. Serum was separated by incubating tubes
containing blood at room temperature for one h to allow clotting
to occur. The tubes were then centrifuged at 1500 Relative Cen-
trifugal Force (RCF) for 15 min and 200 ll of the supernatant was
transferred to disposable glass culture vials. Following this,
200 ll of 20% w/v trichloroacetic acid (TCA) was added to 200 ll
serum in the glass vials to precipitate proteins. This was followed
by addition of 1600 ll of a 0.1% w/v KCl solution as a diluting med-
ium. The glass tube was then placed on ice for 30 min followed by
centrifugation at room temperature for 10 min at 6000 rpm. The
supernatant was placed in a fresh glass culture tube and again cen-
trifuged for 5 min at 6000 rpm. The resulting supernatant was then
directly aspirated into the FAAS machine for analysis.
2.11. Analytical technique
A flame atomic absorption spectrophotometer (Shimadzu, AA-
6300, Tokyo, Japan) was used for determination of lithium ion con-
centration in all samples. Determination of lithium ions concentra-
tion was made at 670.8 nm and a burner height of 7 mm using a
pre-mixed air-acetylene flame. The device was operated in the
absorption mode, using an SR-lithium hollow cathode lamp (SIM-
LabHut Ltd., Gloucestershire, UK) at a current of 8 mA. Least square
linear regression and correlation analysis were carried out on the
calibration curves obtained to determine equation of the line, coef-
ficient of determination and residual sum of squares (RSS). Stan-
dard lithium solutions of 5 lmol/l in KCl (0.1% w/v solution) and
0.1 mmol/l in serum were used to determine the lower limit of
quantification (LLoQ). Five replicates were used and precision
and accuracy determined for each concentration. Linearity, preci-
sion, accuracy and recovery analysis were conducted according to
International Conference on Harmonisation (ICH) guidelines [39].
The accuracy and precision of the method were determined from
analysis of samples at three concentrations, representing the low,
medium and high sections of the standard curves (LQC, MQC and
HQC respectively) [39]. Specifically, concentrations of 0.03, 0.07
and 0.15 mmol/l in KCl 0.1% w/v and of 0.7, 1.2 and 1.8 mmol/l
in serum were used as LQC, MQC and HQC, respectively.
2.12. Statistical analysis
Statistical comparisons were conducted where appropriate
using a t-test or one or two-way analysis of variance (ANOVA). In
all analyses, a p value < 0.05 denoted statistical significance. The
statistical analysis was performed using Graph Pad Prism soft-
ware Version 5.03, CA, USA.
3. Results and discussion
MN technology represents a new and exciting approach for
minimally-invasive TDM and diagnosis [26], allowing sampling of
Extraction efficiency ¼ the measured lithium concentration in the extraction medium
the expected lithium concentration after full recovery
x 100 ð1Þ
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drug molecules from skin ISF without causing pain or bleeding. Our
Group has focused on hydrogel-forming MN, which are hard when
dry but, upon insertion into skin, imbibe ISF from skin and turn
into discrete in situ hydrogel bulbs (Fig. 4b), which can then be
removed intact. Upon removal, an offsite analysis is currently used
to detect the target analyte [20]. However, future work in MN tech-
nology could exploit Internet-based off-site analysis, or potentially
incorporate sensors in situ (‘lab on a chip’ technology) to monitor
the drug of interest [40]. In addition, hydrogel-forming MN offer
further advantages over hypodermic needles, including elimina-
tion of pain, erythema, needle-stick injuries and risk of infections
[18,41].
3.1. Mechanical analysis
As shown in Fig. 3, results obtained from the compression tests
demonstrate that the reduction in MN height increased with an
increase in application force (p < 0.05). The minimum force applied
was 0.18 N/needle, equal to 64.98 N/array, greater than double the
average achievable manual force and close to the maximum man-
ual force value. The maximum force applied was 0.7 N/needle
which equals ten times the average manual force, as described pre-
viously [32]. As shown in Fig. 5b and c, despite application of high
compressional forces, MN arrays did not break when pressed
against the aluminium plate.
3.2. OCT analysis
OCT has the ability to visualize MN penetration into the skin
and observe subsequent dissolving or swelling patterns. In addi-
tion, previous studies have demonstrated its potential as a tool
to study MN penetration depth across the stratum corneum [34].
As shown in Fig. 4a, MN arrays were able to penetrate full thick-
ness neonatal porcine skin upon application, with an insertion
depth and pore size diameter of 229.4 ± 17.7 and 195.58 ± 19 lm,
respectively. As shown in Fig. 4b, following 1 h insertion, MN
arrays had swollen considerably and, in doing so, lost their sharp-
ness, as is apparent in Fig. 4a. Crucially, however, they remained
intact, allowing complete removal. This confirms that swelling
does not result in ejection of MN from the skin and highlights
the safety of our hydrogel-forming MN technology as a tool for
TDM without risk of infection caused by accidental needle-stick
injuries, an issue of concern highlighted as a drawback for MN pre-
pared from other materials [41].
3.3. In-skin swelling
The swelling of MN arrays following insertion into the skin was
investigated in vitro over 1 h. Individual needles on the array
exhibited an increase in height and width of 9.2 ± 2.9% and
19.13 ± 2.9%, respectively. Notably, these hydrogel MN arrays
imbibed PBS fluid and were swollen, but crucially, remained
in situ and again were removed intact.
3.4. Drug uptake and extraction media
As shown in Table 1, extraction of lithium from hydrogel-
forming MN bathed in PBS solutions containing different
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Fig. 3. Percentage reduction in height of needle MN arrays following the applica-
tion of different compressional forces (Means ± SD, n = 3).
Fig. 4a. OCT visualization of dry MN array immediately following insertion into
excised neonatal porcine skin in vitro.
Fig. 4b. OCT visualization of MN array, swollen with lithium solution, after one
hour insertion into excised neonatal porcine skin in vitro.
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concentrations (0.9 and 2 mmol/l) of lithium citrate, and subse-
quently analysed by FAAS, increased with the increased lithium
concentration in the bathing solution. This was the case for all
extraction media. However, extraction of lithium using HCl 2% v/
v (pH = 0.85) was significantly more efficient when compared to
deionized water as an extraction medium (p < 0.05). This may
potentially be due to the associated increased concentration of
protons (H+) in the acidic HCl solution. As protons possess a higher
charge density than lithium ions, and carboxylate ions show
greater affinity to such cations, it is possible that protons are sub-
stituted for the lithium ions of the carboxylate group in the MN
matrix [42]. Similarly, KCl 0.1% w/v solution was studied as a
potential medium for lithium extraction. Statistically, there was
no difference between the extraction efficiency of HCl 2% v/v solu-
tion when compared to 0.1% w/v KCl solution (p < 0.05). Based on
these findings, KCl 0.1% solution was chosen as the extraction med-
ium for the remainder of the study due to its lower potential for
toxicity and greater safety when handling.
3.5. Validation of analytical method using KCl as extraction media
FAAS was used for quantification of lithium in both serum and
KCl solutions. All data were validated according to ICH guidelines
[39]. The slope, R2 and limits of quantification are summarized in
Table 2.
The drug uptake and release findings in combination show the
KCl solution to be a suitable extraction medium for lithium. Fur-
thermore, the presence of potassium potentially suppresses the
ionization of other easily ionized cations, such as sodium, and min-
imizes chemical interference [43,44]. Chemical interference in
transdermal ion analysis has been attributed to small, mobile
cations, such as sodium and potassium, which are present in con-
stant concentrations and can be transported across the skin in a
similar way to lithium [21] and, therefore, could be simultaneously
extracted. Potassium ions in solution do not interfere in the lithium
quantification as they were present at a constant concentration in
all extractions.
3.6. Lithium recovery from MN
As shown in Table 3, lithium extraction efficiency from spiked
MN was 88.68 ± 7.8%.
This percentage recovery indicates that extraction of lithium
from hydrogel-forming MN using the method developed is highly
efficient. Significantly, the percentage recovery in this study falls
within recommended guidelines which accept deviation of
±0.3 mmol/l (or 20%) as acceptable error limits based on United
States Food and Drug Administration (FDA) guidelines [45].
3.7. In vitro lithium uptake
As shown in Fig. 6, a significant increase (p < 0.05) in extracted
lithium concentration was observed when MN insertion time was
increased from 30 min to 1 h. Notably, this effect was observed for
both lithium concentrations (0.9 and 2 mmol/l). Although no sig-
nificant difference (p > 0.05) was observed between extracted
lithium values following in vitro MN application after 30 min, a
highly significant difference (p < 0.01) was observed in lithium
Table 1
Lithium extracted (lmol) using different extraction media (Mean ± SD, n = 4).
Extracting media Concentration extracted
from MN bathed in
0.9 mmol/l solution
Concentration extracted
from MN bathed in
2 mmol/l solution
Deionized water 4.5 ± 2.6 318.1 ± 12.7
HCl 2% v/v 87.7 ± 5.3 131.3 ± 12.1
KCL 0.1% w/v 83.7 ± 5.9 123.5 ± 8.3
Table 2
Calibration curve properties for lithium in serum and KCl 0.1% w/v solution (n = 5).
Slope y-Intercept R2 LoQ (mmole/l)
Serum 0.0161 0.0004 0.99 0.1
KCl 0.1530 0.0006 0.99 0.005
Table 3
Recovery of lithium from spiked MN (Mean recovery ± SD, n = 10).
Li+ concentration spiked
onto MN (mmol/l)
Extracted
concentration (mmol/l)
% Recovery
1.08 0.95 ± 0.08 88.68 ± 7.8
Fig. 5. Digital microscope images of hydrogel-forming MN following application of
compressional forces (0.18 and 0.7 N/needle) (Means ± SD, n = 3). (a) 19  19 MN
array before application of compressional force. (b) 19  19 MN array after
application of compressional force equal to 0.18 N/needle. (c) 19  19 MN array
after application of compressional force equal to 0.7 N/needle.
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concentrations extracted from MN following one h application.
Crucially, these results demonstrate that hydrogel-forming MN
have the ability to definitively differentiate between therapeutic
and toxic ISF lithium concentrations following an application time
of only 1 h. This time frame confers a substantial practical advan-
tage when compared with other proposed transdermal TDMmeth-
ods, such as RI, which may require an application time of up to 5 h
[21]. Following application of MN arrays, diffusion along the con-
centration gradient is the main driving force for solute movement
into the MN polymeric matrix. It is, therefore, reasonable to
assume that diffusion of lithium into the MN matrix is directly
related to its concentration in the Franz cells. In this study, the
application time of 1 h appears to reflect the minimum time
required for a sufficient volume of fluid to enter the MN array
and, subsequently, allow differentiation between a therapeutic
and toxic concentration of the analyte of interest. This, therefore,
may be the limiting factor in a minimum application time of 1 h
using hydrogel-forming MN. In addition, although lithium
concentrations from the two Franz-cell chambers were not statis-
tically different following a MN application time of 30 min, they
were still quantifiable using FAAS analysis. As such, these findings
led us to proceed to the in vivo component of the study.
3.8. In vivo MN lithium monitoring
Due to its narrow therapeutic target range, and its variable
serum half-life, which increases with chronic administration [35],
regular lithium TDM is required in order to avoid both sub-
therapeutic and toxic effects. Toxicity typically occurs when the
serum concentration exceeds 1.5 mmol/l for a prolonged period,
e.g. several days. As the serum concentration increases, toxic
effects include tremor, GIT and respiratory complications, seizures,
and finally death [4]. The doses of lithium administered to SD rats
in this in vivo study were based on both the paediatric dose (15–
60 mg/kg/day, administered in three to four doses) and the adult
dose (900–1800 mg/day  15 mg/kg/day, usually divided in two
doses) as indicated for treatment of acute episodes of bipolar
mania [4].
Although the kinetic profiles of lithium in humans and rodents
differ (Table 4) and identical serum concentration profiles may not
be reproducible [46], the study was undertaken as a vital in vivo
TDM proof of concept.
In this study, MN arrays were used to capture ISF from six SD
rats following administration via oral gavage of lithium carbonate
solution. The six rats were divided into two groups and the 1 h
application time for MN arrays was chosen based on the findings
from the in vitro work previously conducted.
As shown in Fig. 7 the mean serum lithium concentration for
Group 1 rats dosed with 15 mg/kg lithium carbonate was
0.1 ± 0.08 mmol/l. In comparison, Group 2 rats dosed with 30 mg/
kg lithium carbonate displayed a statistically significant (p < 0.05)
difference in serum concentration of 0.24 ± 0.06 mmol/l. Similarly,
when lithium levels extracted from MN applied for one hour were
analysed, the Group 1 and Group 2 rats displayed concentrations of
4.0 ± 2.5 lmol/l and 4.9 ± 2.2 lmol/l respectively, equivalent to a
percentage increase of 22.5%. Although not statistically significant
(p > 0.05) these findings suggest hydrogel-forming MN are capable
of differentiating between therapeutic and toxic concentrations of
lithium in vivo after only one h application time. As transdermal
drug extraction and analysis is a multi-factorial procedure, affected
by many physicochemical and pharmacokinetic factors, it is our
opinion that this variability is an expected challenge of a novel,
proof of concept TDM process. However, the results obtained
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Fig. 6. Concentration of lithium extracted from hydrogel-forming MN after
insertion into neonatal porcine skin mounted on modified Franz cells and bathed
on the underside by 0.9 and 2 mmol/l lithium citrate in PBS (Means ± SD, n = 4).
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Table 4
Pharmacokinetic parameters of lithium in humans (Mean ± SD) and rats [46].
Half-life (h) Volume of
distribution (L/kg)
Clearance (ml/minute)
Rat 6.07 1.13 2.15
Human 28.9 ± 7.9 0.79 ± 0.34 24.4 ± 8.0
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Fig. 7. Serum lithium concentration detected in plasma versus levels detected from MN arrays inserted in Sprague–Dawley rats for 1 h following administration via oral
gavage of 15 mg/kg lithium carbonate (Group 1) and 30 mg/kg lithium carbonate (Group 2) respectively. (Mean ± SD, n = 3) ( = significant).
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demonstrate that MN can capture a quantifiable amount of lithium
from ISF following a period of only 1 h application in vivo. Notably,
lithium ISF concentration is not instantaneously related to serum
concentration [21] and, accordingly, no lithium was detected from
MN arrays inserted into the rats’ backs for 1 h prior to dosing. This
served as an informative negative control. This strongly suggests
that the swelling of MN was due to uptake of ISF containing
lithium, rather than any lithium potentially present in rat perspira-
tion. In addition, our polymeric MN systems were removed macro-
scopically intact after skin insertion, leaving no detectable polymer
behind.
Toxic lithium concentration in serum appears one or two days
before toxicity symptoms due to a well-established latency effect
[6]. Therefore, clinical presentation of lithium toxicity may not be
supported by blood level and vice versa [6]. The concept of outpa-
tients using hydrogel-forming MN for lithium TDM would be a sig-
nificant breakthrough both in routine TDM and in anticipating
occurrence of toxic symptoms, facilitating early intervention
before serious side effects occur. This could, in turn, save time
and costs to the health system, not to mention the obvious patient
benefit. As therapeutic lithium levels are based on the serum sam-
ples taken in the morning, usually 12 h following the last adminis-
tered dose [10], patients could apply the MN for one hour in the
morning, and then send them to the nominated laboratory for
analysis. Lithium from these MN would then be extracted and
analysed and the results could potentially be sent to the patients
within 24 h, allowing rapid optimization of dose. The current study
has the limitations of being carried out in small number of animals.
However, as a proof of concept, the obtained animal data are,
nonetheless, exiting. Furthermore, the current study was con-
ducted using therapeutic lithium doses, as administration of toxic
doses was not ethically acceptable. Nevertheless, the agreement
between the extraction of lithium from MN and lithium serum
concentration in the two groups of rats suggests real potential
for using MN as a therapeutic monitoring tool for lithium.
4. Conclusion
This study demonstrates, for the first time, the potential of
hydrogel-forming MN as a means of transdermal lithium TDM
using ISF as a sampling reservoir. We have successfully demon-
strated hydrogel-forming MN have the potential as a means of
minimally-invasive lithium TDM. The findings of this study
strongly suggest that hydrogel-forming MN offer an exciting,
newmeans of lithium TDM. Future work will focus on optimization
of MN application time, with respect to ensuring precise quantifi-
cation of lithium concentration, potentially including ‘lab-on-a-
chip’ or MN sensor technology to deliver an concentration easily
interpreted by both clinicians and patients.
It is expected that hydrogel-forming MN will likely focus on
minimally-invasive home-based monitoring, ensuring compliance
and preventing toxicity. For home sampling, a short training ses-
sion may not even be necessary. The patient may learn the tech-
nique from an instruction leaflet or an associated website.
Regarding sample extraction and analysis, there are currently no
portable devices for analysis to be used by a patient. This concept
has enormous potential, especially if an analytical device with a
display screen or colour change indicator is developed. This would
simply provide the clinician and patient with a ‘Yes/No-High/Low’
feedback, allowing them to make simple pre-ordained decisions
without involvement of health care professionals. Improved rates
of lithium TDM will undoubtedly minimize the chances of adverse
events. The existing gap between the standard and current practice
of biochemical monitoring of lithium treatment [47] might be
replaced with a system such as our hydrogel-forming MN system
that can offer frequent, simple and minimally-invasive monitoring
in conjunction with fast analysis and feedback. Finally, although
this study focussed on the quantification of lithium, it could
equally be implemented in detection and quantification of other
analytes of interest, such as potassium and sodium. These are often
deranged in cardiac and renal disorders and as they are also phys-
iological cations, they should be readily detectable using our novel
hydrogel-forming MN technology.
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